Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Fast vs. slow corneal treatment: which works better for keratoconus?

NCT ID NCT07194538

Disease control Sponsor: Clinical Hospital Centre Zagreb Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study followed 20 people with progressive keratoconus for one year after they received either a standard 30-minute or a faster 10-minute corneal cross-linking treatment. The goal was to see how well each method stopped the disease from getting worse and improved eye shape and vision. Results will help doctors choose the best treatment option.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

20 people

The number who actually took part.

Started

May 2021

Finished

Jan 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with progressive keratoconus treated at University Hospital Centre Zagreb (Croatia).

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Progressive keratoconus documented on serial Scheimpflug tomography within the prior 12 months (ABCD/K-metrics and/or pachymetry). * Clear corneal axis (no visually significant scarring). * Corneal thickness 370 μm or more Exclusion Criteria: * No central corneal scars, prior chemical burns, severe corneal infection, or ocular surface disease. * No pregnancy and lactation during treatment.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Keratoconus are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

keratoconus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Keratoconus

Contacts and locations

Locations

  • University Hospital Centre Zagreb

    Zagreb, 10 000, Croatia

More trials for these conditions

Other studies related to the condition(s) this trial covers.